DR. CHRIS BOYLE is a life sciences lawyer and qualified veterinarian who advises and litigates in the highly regulated fields of human and veterinary medicinal products, medical devices, biocides, chemicals, food, and feed. In addition to his advisory and litigation work, Chris coordinates multi-jurisdictional compliance projects and supports complex life sciences corporate transactions and private equity deals by providing valuable legal and industry insights and specialist due diligence.
For animal health clients, Chris provides advice across the entire lifecycle of veterinary medicines from pre-authorization to commercialization. This includes development, licensing, co-marketing and commercial agreements, clinical trials, manufacturing, regulatory approval and market access, novel therapies, regulatory data protection, supplementary protection certificates (SPCs), advertising and promotional campaigns, product recalls, suspension of marketing authorizations, off-label prescribing issues, and import and export issues. Chris additionally advises clients in relation to animal devices, diagnostics, feed, and feed supplements. When providing his advice, Chris recognizes the crucial interaction between animal health and human and environmental health and advises companies adopting a “One Health” approach. Chris founded and chairs the Sidley Animal Health Legal Forum (AHLF), a network for animal health professionals, regulatory affairs colleagues, and investors who meet regularly to share best practices and to discuss legal and regulatory issues the animal health industry is facing.
For biopharma and pharma clients, Chris advises and litigates across a broad spectrum of regulatory frameworks. This includes advising on valuable IP regulatory rights such as orphan-drug market exclusivity, pediatric rewards, SPCs, and regulatory data protection rights. On market access issues, Chris assists clients from pre-marketing authorization through to commercialization phases. For instance, Chris helps guide clients through the legal and regulatory requirements in Health Technology Assessments to present the best value to payors, including the utilization of Real World Evidence (RWE) to address gaps in clinical trial data. Chris has successfully supported clients in challenging unfavorable decisions of regulatory bodies such as the EMA, MHRA and UK Home Office, and health technology authorities, such as NICE, and in enforcing regulatory exclusivities in the courts. Chris is also actively involved in the development of the new EU Pharmaceutical Law Package, IP Package, and the Critical Medicines Act.
In the MedTech sector, Chris helps clients to adapt to the evolving regulatory frameworks under the new medical device regulations (MDR and IVDR), and he advises on the many classification and borderline issues that arise as the legal frameworks try to keep pace with technology, including companion diagnostics, wearables, RWE, and AI.
Chris advises companies on novel food authorizations, human and animal supplements, food and feed claims, food incidents, product withdrawals, and recalls.
Chris is a solicitor-advocate, experienced in representing clients before the UK and EU courts. He is acting for a pharmaceutical company in high-value, follow-on damages proceedings in the UK concerning the intersection of competition, regulatory, and patent law. Chris acted in two appeals before the UK Supreme Court and a month-long trial before the High Court, winning the 2022 LMG Life Sciences “Impact Case of the Year” and the 2022 Managing IP awards “UK Impact Case of the Year.” Chris has also helped to successfully enforce orphan-drug market exclusivity before the General Court in Luxembourg.
Chris has received acknowledgement from numerous industry ranking guides:
- Legal 500 UK 2025 – Named as “Next Generation Partner” for Life Sciences and Healthcare, where clients comment: “Chris Boyle is a vet as well as lawyer, so he understands the animal health industry first hand and speaks our language! Chris has instigated an Animal Health Legal Forum, bringing together others in the industry, which is a great innovation.”
- Chambers UK 2025 – Named as “Up and Coming” for Life Sciences: Regulatory, where clients noted that “Chris provides excellent client service, is very quick to respond to our needs and always keeps us updated on unplanned challenges. He is thoughtful and proactive in his presentations. ” “Chris is an outstanding individual. He is highly professional in listening and reflecting back his understanding of the evidence and his life science background is helpful.” “Chris is a real stellar performer and a future shining light in regulatory life sciences work.”
- Legal 500 UK 2024 – Named as “Rising Star” for Life Sciences and Healthcare, where clients comment: “Chris Boyle has a very reassuring presence, and is calm and reflective, and always appreciates the priority of the client. His advice is concise and always provided with the realities of the business environment in mind.”
- Legal 500 UK 2023 – Named as “Rising Star” for Life Sciences and Healthcare, where clients noted that “Chris Boyle is an absolute superstar as a Senior Managing Associate. He is tremendously clever, prodigiously hard working and would be at the top of my list of people to have on any team. He also has a strong scientific background in life sciences, which is invaluable.” “Chris Boyle is a qualified veterinarian and life-sciences lawyer who uses his scientific background to great effect when advising his clients. Great practical advice.”
Chris speaks regularly on hot topics in regulatory life-sciences at international conferences.